Specifically, HRC reported total revenue and after-tax profit of VND 89 billion and VND 22 billion in Q3, exceeding the quarterly plan by approximately 5% and 29%, respectively.
For the first nine months of the year, cumulative total revenue and after-tax profit reached nearly VND 188 billion and VND 27 billion, respectively. The nine-month profit surpassed the annual plan by over 3%, while total revenue achieved more than 85% of the target.
|
Business results for the first 9 months of 2025 of HRC. Unit: Billion VND
Source: HRC
|
For Q4, HRC aims to achieve an extraction volume of nearly 1,238 tons, processing volume of approximately 2,025 tons, and sales volume of around 1,299 tons.
In terms of financial targets, Q4 total revenue is projected at VND 68.3 billion, a 45% decrease compared to the same period last year. This includes rubber revenue of nearly VND 65 billion, processing revenue of over VND 2.2 billion, financial revenue of VND 183 million, and other revenue of VND 915 million. Notably, in Q4/2024, the company recorded an extraordinary other income of over VND 28 billion from the liquidation and sale of fixed assets.
Consequently, HRC‘s pre-tax and after-tax profit targets for Q4/2025 are expected to decline by 91% and 92%, respectively, to VND 5.9 billion and VND 4.5 billion.
On the other hand, if these targets are met, HRC will exceed its full-year revenue and after-tax profit goals by 16% and 20%, respectively.
– 5:40 PM, November 12, 2025
How Did Deo Ca Perform in the First Nine Months of 2025?
In the first nine months of 2025, HHV achieved a cumulative revenue of over 2.595 trillion VND, marking a nearly 13% increase. The company’s after-tax profit reached almost 477 billion VND, a significant growth of nearly 30% compared to the same period in 2024. This performance has successfully fulfilled 86% of the annual plan for 2025.
Q3 Pharmaceutical Sector: Sustaining Growth Momentum
The strategic restructuring of product portfolios, coupled with the advantages gained from the 2024 year-end policies, has significantly bolstered the performance of most pharmaceutical companies in Q3 2025.
Unveiling the Top Performers Driving Business Success in the First Nine Months of 2025
As of the end of Q3 2025, the financial performance of listed companies has revealed notable highlights, with leading enterprises continuing to surge ahead in both revenue and profitability.
Navico Launches Supply Channel for JBS Brazil, Delivers First Fish Shipment as Q3 Exports Surpass $1.5 Trillion
The first container shipment of tilapia to JBS marks Nam Viet Corporation’s (Navico, HOSE: ANV) entry into the Brazilian market, following the company’s impressive Q3 performance, which saw a 71% surge in export revenue and nearly tenfold increase in net profit year-over-year.
VC3’s Q3 Net Profit Surges 1.5x Year-on-Year, Driven by Bao Ninh 2 Project Revenue Recognition
Fueled by robust revenue from its real estate projects, Nam Mekong Group Corporation (HNX: VC3) reported a 50% year-over-year surge in net profit for Q3 2025.
